Cannabis sativa and dystonia secondary to Wilson's disease

Movement Disorders

Volumn 20, Issue 1, 2005, Pages 113-115

  Uribe Roca, M Claudia ^a   Micheli, Federico ^a   Viotti, Ricardo ^b  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b Inst de Rehabilitacion del Lisiado   (Argentina)

Author keywords

Cannabis; Dystonia; Wilson's disease

Indexed keywords

CANNABIS; CLONAZEPAM; DIAZEPAM; PAROXETINE; PENICILLAMINE; TRIENTINE;

ADULT; ANXIETY; ARTICLE; BRADYKINESIA; CASE REPORT; DEPRESSION; DISEASE EXACERBATION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; DYSTONIA; FOLLOW UP; GAIT DISORDER; HUMAN; HYPERSALIVATION; INSOMNIA; IRRITABILITY; MALE; MUSCLE RIGIDITY; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SMOKING; SUICIDE ATTEMPT; TREMOR; WALKING; WILSON DISEASE; XEROSTOMIA;

ADULT; CANNABIS; DISABILITY EVALUATION; DYSTONIC DISORDERS; HEPATOLENTICULAR DEGENERATION; HUMANS; MALE; PHYTOTHERAPY; PLANT PREPARATIONS; TREATMENT OUTCOME;

EID: 14044272830     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20268     Document Type: Article

References (16)

1. Voelker R. NIH Panel says more study is needed to assess marijuana's medicinal use. JAMA 1997;277:867-868.
2. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-48.
3. 9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette Syndrome: a 6-week randomized trial. J Clin Psychiatry 2003;64:459-465.
4. Sieradzan K, Fox SH, Dick J, Brotchie JM. The effects of cannabinoid receptor agonist nabilone on L-DOPA-induced dyskinesia in patients with idiopathic Parkinson's disease. Mov Disord 1998; 13(Suppl.):29.
5. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983;13:669-671.
6. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30: 277-282.
7. Starosta-Rubinstein S, Young AB, Kluin K, Hill G, Aisen AM, Gabvielsen T, Brewer GJ. Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. Arch Neurol 1987;44:365-370.
8. Lenz FA, Suarez JI, Metman LV, Reich SG, Karp BI, Hallet M, Rowland LH, Dougherty PM. Pallidal activity during dystonia: somatosensory reorganization and changes with severity. J Neurol Neurosurg Psychiatry 1998;65:767-770.
9. Mitchell IJ, Luquin R, Boyce S, Clarke CE, Robertson RG, Sambrook MA, Crossman AR. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord 1990;5:49-54.
10. Fox SH, Kellet M, Moore AP, Crossman AR, Brotchie JM. Randomized, double-blind placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002;17:145-149.
11. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990;87:1932-1936.
12. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.
13. Miller AS, Walker JM. Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus. Eur J Pharmacol 1998;352:199-205.
14. Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 1996;308:161-164.
15. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003;2:291-298.
16. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003; 112:393-402.